FDA Approves Miplyffa for Treatment of Niemann-Pick Disease, Type C

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 1, 2024.

By Lori Solomon HealthDay Reporter

MONDAY, Sept. 30, 2024 -- The U.S. Food and Drug Administration has approved Miplyffa (arimoclomol), an oral medication for the treatment of Niemann-Pick disease, type C (NPC).

Miplyffa, in combination with the enzyme inhibitor miglustat, is approved to treat neurological symptoms associated with NPC in adults and children aged 2 years and older. The approval received priority review, orphan drug, rare pediatric disease, fast track, and breakthrough therapy designations.

The approval is based on results from a randomized, double-blind, placebo-controlled 12-month trial in patients (ages 2 to 19 years) with a molecularly confirmed diagnosis of NPC. The analysis included 50 patients randomly assigned (2:1) to treatment with weight-adjusted Miplyffa (31 to 124 mg) or placebo orally three times per day. Miplyffa resulted in slower disease progression as measured by the rescored four-domain NPC Clinical Severity Scale score. The most common side effects of Miplyffa treatment included upper respiratory tract infection, diarrhea, and decreased weight.

"The first-ever approval of a safe and effective drug option for NPC will undoubtedly support the essential medical needs of those suffering," Janet Maynard, M.D., director of the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine in the FDA Center for Drug Evaluation and Research, said in a statement.

Approval of Miplyffa was granted to Zevra Therapeutics.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-10-01 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords